Skip to main content

Advertisement

SpringerLink
Log in

Midkine confers Adriamycin resistance in human gastric cancer cells

  • Research Article
  • Published:
Tumor Biology

Abstract

Midkine (MDK) is a heparin-binding molecule involved in the regulation of growth and differentiation during embryogenesis, which is overexpressed in most of human malignant tumors and may act as an oncoprotein. The aim of the current study was to investigate the mechanism of MDK involved in the Adriamycin (ADR) resistance in human gastric cancer cells in vitro. We found that Adriamycin-resistant SGC7901 (SGC7901/ADR) exhibited 58.6-fold greater resistance to ADR compared with Adriamycin-sensitive SGC7901 cell line. MDK mRNA and protein expression levels were significantly higher in SGC7901/ADR than in SGC7901. To gain a deeper insight into the role of MDK in SGC7901/ADR, we stably transfected Adriamycin-sensitive SGC7901 with viral vector expressing MDK. Our result showed that multidrug resistance type I (MDR1) was found in SGC7901/ADR, not in SGC7901 by RT-PCR regardless of MDK transfection. P-Glycoprotein, which is the MDR1-coded protein, was found in SGC7901/ADR, not in SGC7901 by Western blot regardless of MDK transfection. We investigated whether an activation of the tyrosine kinase pathway would change the drug resistance phenotype with MDK transfection. Western blot results showed the upregulation of phosphorylated protein kinase B (AKT) and phosphorylated extracellular signal-regulated protein kinase (ERK) in Adriamycin-sensitive SGC7901 cell by MDK transfection accompanied with drug resistance to ADR, although the level of AKT and ERK protein expression did not change, so our results suggested that MDK, which can activate AKT and ERK by phosphorylation, induced the Adriamycin resistance in gastric cancer cells. Understanding the molecular mechanisms, driving MDK-induced ADR resistance, will provide benefits in developing new therapies for gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Grémy G, Couillault C, Lajémi M, Piatier-Tonneau D, Zaborski P, Eveno E, Auffray C, Imbeaud S. Deciphering cellular states of innate tumor drug responses. Genome Biol. 2006;7(3):R19.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kerzerho J, Adotevi O, Castelli FA, Dosset M, Bernardeau K, Szely N, Lang F, Tartour E, Maillere B. The angiogenic growth factor and biomarker midkine is a tumor-shared antigen. J Immunol. 2010;185:418–23.

    Article  CAS  PubMed  Google Scholar 

  4. Muramatsu T. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86:410–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Zhao ZQ, Yang S, Lu HS. Expression of midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival. Mol Med Report. 2012;5:415–9.

    CAS  Google Scholar 

  6. Grzelinski M, Steinberg F, Martens T, Czubayko F, Lamszus K, Aigner A. Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia. 2009;11:145–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Xu Y, Qu X, Zhang X, Luo Y, Zhang Y, Luo Y, Hou K, Liu Y. Midkine positively regulates the proliferation of human gastric cancer cells. Cancer Lett. 2009;279:137–44.

    Article  CAS  PubMed  Google Scholar 

  8. Du WW, Yang BB, Yang BL, Deng Z, Fang L, Shan SW, Jeyapalan Z, Zhang Y, Seth A, Yee AJ. Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy. PLoS One. 2011;6:e26396.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem. 2002;132:359–71.

    Article  CAS  PubMed  Google Scholar 

  10. Ota K, Fujimori H, Ueda M, Shiniriki S, Kudo M, Jono H, Fukuyoshi Y, Yamamoto Y, Sugiuchi H, Iwase H, Shinohara M, Ando Y. Midkine as a prognostic biomarker in oral squamous cell carcinoma. Br J Cancer. 2008;99:655–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yokota K, Hirano T, Urata N, Yamauchi N, Hattori MA. Upregulation of P-glycoprotein activity in porcine oocytes and granulosa cells during in vitro maturation. J Reprod Dev. 2011;57:322–6.

    Article  CAS  PubMed  Google Scholar 

  12. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 2005;117:376–80.

    Article  CAS  PubMed  Google Scholar 

  14. Tong Y, Mentlein R, Buhl R, Hugo HH, Krause J, Mehdorn HM, Held-Feindt J. Overexpression of midkine contributes to anti-apoptotic effects in human meningiomas. J Neurochem. 2007;100:1097–107.

    Article  CAS  PubMed  Google Scholar 

  15. Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, Muramatsu T, Michikawa M. Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem. 1999;73:2084–92.

    CAS  PubMed  Google Scholar 

  16. Sandra F, Harada H, Nakamura N, Ohishi M. Midkine induced growth of ameloblastoma through MAPK and Akt pathways. Oral Oncol. 2004;40:274–80.

    Article  CAS  PubMed  Google Scholar 

  17. Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002;277:35990–8.

    Article  CAS  PubMed  Google Scholar 

  18. Dai LC, Wang X, Yao X, Min LS, Ping JL, He JF. Antisense oligonucleotides targeting midkine inhibit tumor growth in an in situ human hepatocellular carcinoma model. Acta Pharmacol Sin. 2007;28:453–8.

    Article  CAS  PubMed  Google Scholar 

  19. Dai LC, Yao X, Wang X, Niu SQ, Zhou LF, Fu FF, Yang SX, Ping JL. In vitro and in vivo suppression of hepatocellular carcinoma growth by midkine-antisense oligonucleotide-loaded nanoparticles. World J Gastroenterol. 2009;15:1966–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, McCubrey JA. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle. 2011;10:3003–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget. 2011;2:538–50.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Science Foundation of China (no.30770993 and 81000943) and Key Laboratory Programme of Education Department of Liaoning Province (no.LS2010165).

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Breast Surgery, Department of Surgical Oncology, Research Unit of General Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, 110001, People’s Republic of China

    Ying-ying Xu, Xiao-yun Mao & Feng Jin

  2. Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, People’s Republic of China

    Yong-xi Song, Feng Zhao, Zhen-ning Wang & Hui-mian Xu

  3. 97K, China Medical University, Shenyang, People’s Republic of China

    Wei-xu Zhang

Authors
  1. Ying-ying Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao-yun Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yong-xi Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Feng Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhen-ning Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei-xu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hui-mian Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Feng Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Feng Jin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, Yy., Mao, Xy., Song, Yx. et al. Midkine confers Adriamycin resistance in human gastric cancer cells. Tumor Biol. 33, 1543–1548 (2012). https://doi.org/10.1007/s13277-012-0406-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0406-3

Keywords

Search

Navigation